Regeneron

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Regeneron 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About REGN

Regeneron Pharmaceuticals, Inc. is a biotechnology company, which engages in the discovery, invention, development, manufacture, and commercialization of medicines. Its product portfolio includes the following brands: Dupixent, Evkeeza, Eylea, Inmazeb, and Kevzara. 

CEO
Leonard S. Schleifer
CEOLeonard S. Schleifer
Employees
15,410
Employees15,410
Headquarters
Tarrytown, New York
HeadquartersTarrytown, New York
Founded
1988
Founded1988
Employees
15,410
Employees15,410

REGN Key Statistics

Market cap
82.19B
Market cap82.19B
Price-Earnings ratio
18.94
Price-Earnings ratio18.94
Dividend yield
0.45%
Dividend yield0.45%
Average volume
871.37K
Average volume871.37K
High today
$790.00
High today$790.00
Low today
$775.52
Low today$775.52
Open price
$782.83
Open price$782.83
Volume
289.42K
Volume289.42K
52 Week high
$821.11
52 Week high$821.11
52 Week low
$476.49
52 Week low$476.49

Stock Snapshot

Regeneron(REGN) stock is priced at $777.57, giving the company a market capitalization of 82.19B. It carries a P/E multiple of 18.94 and pays a dividend yield of 44.8%.

During the trading session on 2026-02-09, Regeneron(REGN) shares reached a daily high of $790.00 and a low of $775.52. At a current price of $777.57, the stock is +0.3% higher than the low and still -1.6% under the high.

Trading volume for Regeneron(REGN) stock has reached 289.42K, versus its average volume of 871.37K.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

The stock's 52-week range extends from a low of $476.49 to a high of $821.11.

REGN News

TipRanks 8h
Regeneron price target raised to $975 from $865 at Guggenheim

Guggenheim raised the firm’s price target on Regeneron (REGN) to $975 from $865 and keeps a Buy rating on the shares. The firm, which updated its model after ea...

Simply Wall St 3d
Regeneron Data On EYLEA HD Dosing Shapes Retinal Disease Outlook

Regeneron Pharmaceuticals (NasdaqGS:REGN) is presenting final long term Phase 3 data from its QUASAR and ELARA trials for EYLEA HD at a major ophthalmology conf...

Regeneron Data On EYLEA HD Dosing Shapes Retinal Disease Outlook
TipRanks 3d
Regeneron Targets Early Myeloma: New Phase 3 Trial Pits Linvoseltamab Against Daratumumab

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Study Overview: Regeneron Pharmaceuticals is launching a Phase 3 trial ti...

Analyst ratings

72%

of 29 ratings
Buy
72.4%
Hold
27.6%
Sell
0%

More REGN News

TipRanks 3d
Regeneron’s REGN9533 Trial Completion Signals Quiet but Important Progress in Clot-Blocking Drugs

Regeneron Pharmaceuticals (REGN) announced an update on their ongoing clinical study. Regeneron’s latest update on its early-stage trial of REGN9533 marks an i...

Nasdaq 4d
Regeneron Q1 2025 Earnings Call Transcript

AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX ADP SBUX MRNA AAPL TSLA AMZN META AMD NVDA PEP COST ADBE GOOG AMGN HON INTC INTU NFLX AD...

Regeneron Q1 2025 Earnings Call Transcript
TipRanks 5d
Regeneron’s Expanding AI Use Raises Data Privacy, Regulatory and Market Risks

Regeneron Pharmaceuticals (REGN) has disclosed a new risk, in the Technology category. Regeneron Pharmaceuticals faces growing exposure as it expands the use o...

Simply Wall St 5d
A Look At Regeneron Pharmaceuticals Valuation After Q4 2025 Beat And New EYLEA HD Data

Regeneron Pharmaceuticals (REGN) has just paired a Q4 2025 earnings beat with fresh momentum in its eye franchise, as new EYLEA HD data head to the Angiogenesis...

A Look At Regeneron Pharmaceuticals Valuation After Q4 2025 Beat And New EYLEA HD Data
Simply Wall St 7d
Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron?

Regeneron Pharmaceuticals recently reported Q4 2025 and full-year 2025 results showing modest year-on-year revenue and earnings growth, alongside ongoing share...

Does Modest 2025 Results and New EYLEA HD Data Shift the Bull Case for Regeneron?

People also own

Based on the portfolios of people who own REGN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.